| __timestamp | Arrowhead Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 17986000 |
| Thursday, January 1, 2015 | 34718089 | 32480000 |
| Friday, January 1, 2016 | 40998209 | 68081000 |
| Sunday, January 1, 2017 | 32022880 | 169906000 |
| Monday, January 1, 2018 | 19110051 | 248932000 |
| Tuesday, January 1, 2019 | 26556257 | 354100000 |
| Wednesday, January 1, 2020 | 52275890 | 433300000 |
| Friday, January 1, 2021 | 80981000 | 583300000 |
| Saturday, January 1, 2022 | 124431000 | 752700000 |
| Sunday, January 1, 2023 | 90932000 | 887600000 |
| Monday, January 1, 2024 | 98761000 | 1007200000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc. have shown contrasting trends in their SG&A management from 2014 to 2023. Neurocrine Biosciences has seen a significant increase in SG&A expenses, peaking at approximately 888% of their 2014 levels by 2023. This rise reflects their aggressive expansion and investment in administrative capabilities. In contrast, Arrowhead Pharmaceuticals has managed a more moderate increase, with their SG&A expenses growing by around 404% over the same period. This suggests a more conservative approach to cost management. Notably, data for Neurocrine Biosciences in 2024 is missing, indicating potential changes in their financial reporting or strategy. Understanding these trends can provide valuable insights for investors and stakeholders in the biotech industry.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Vertex Pharmaceuticals Incorporated or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: GSK plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Dr. Reddy's Laboratories Limited and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Novavax, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.